DOC · Healthpeak Properties, Inc.
$20.79
-0.02 (-0.10%)
At close · Aug 14
Market Cap
$14.34B
Shares
689.53M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.79
Open$20.77
Day$20.70–20.89
52W close$15.78–22.82
Avg vol 30d5.9M
Short int24.4M · 3.5% float · 3.9d
Short vol43%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−2%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
71%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+20%
trailing
YTD return
+29%
this year
Relative strength
+6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $21 › 200d $18 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +97 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.54% of float · ▲ +1.8% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
738 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
EPS growth
−72%
Y/Y
Valuation
P/E 59.4
in line
Buyback
$500.0M
authorized
Balance sheet
$9.4B
net debt
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−19%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Diluted earnings per common share
· Full Year 2026
$0.48 – $0.52
Prior guidance
period ended
· from the 8-K filed Oct 23, 2025
G&A guidance
· this year
up to -5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
71%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $21 › 200d $18 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +97 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.54% of float · ▲ +1.8% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
738 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $16
Now $21 · 71%
Range high $23
vs 200-day avg +13%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Janus Living Adjusted EBITDAre non-GAAP | $79M | Q2 2026 | — |
| Janus Living Total Adjusted Net Operating Income non-GAAP | $58M | Q2 2026 | — |
| Lab new lease executions | 222,000 | Q2 2026 | — |
|
|
|||
| Lab occupancy | 78.5% | Q2 2026 | — |
| Lab renewal lease executions | 159,000 | Q2 2026 | — |
|
|
|||
| Lab Same-Store Adjusted NOI Growth non-GAAP | -3.2% | Three Months Ended June 30, 2026 | — |
|
|
|||
| Net Debt to Adjusted EBITDAre non-GAAP | 4.7 | Q2 2026 | — |
|
|
|||
| Outpatient Medical new lease executions | 327,000 | Q2 2026 | — |
|
|
|||
| Outpatient Medical occupancy | 90.7% | Q2 2026 | — |
| Outpatient Medical renewal lease executions | 916,000 | Q2 2026 | — |
|
|
|||
| Outpatient Medical Same-Store Adjusted NOI Growth non-GAAP | 2.5% | Three Months Ended June 30, 2026 | — |
|
|
|||
| Senior Housing Same-Store Adjusted NOI Growth non-GAAP | 19.2% | Three Months Ended June 30, 2026 | — |
|
|
|||
| Total Same-Store Adjusted NOI Growth non-GAAP | 1.8% | Three Months Ended June 30, 2026 | — |
| Lab cash releasing spreads on renewals | 3.5% | Q1 2026 | — |
|
|
|||
| Outpatient Medical cash releasing spreads on renewals | 5.4% | Q1 2026 | — |
|
|
|||
| Total Outpatient Medical and Lab new and renewal lease executions | 1.2M | Q1 2026 | — |
| Asset sales and loan repayments | $511M | Full Year 2025 | — |
| Lab renewal term | 84 | Q4 2025 | — |
| Lab retention | 72% | Full Year 2025 | — |
| Lab Same-Store Cash (Adjusted) NOI growth non-GAAP | 1.5% | Full Year 2025 | — |
| New and renewal lease executions | 2.1M | Q4 2025 | — |
| Outpatient Medical retention | 79% | Full Year 2025 | — |
| Outpatient Medical Same-Store Cash (Adjusted) NOI growth non-GAAP | 3.9% | Full Year 2025 | — |
| Total Merger-Combined Same-Store Cash (Adjusted) NOI growth non-GAAP | 3.9% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOC
this stock
Healthpeak Properties, Inc.
|
$14.34B | +29.3% | +4.5% | 59.4 | 3.5% |
|
WELL
Welltower Inc.
|
$162.55B | +26.9% | +35.6% | 114.6 | 2.5% |
|
VTR
Ventas, Inc.
|
$45.66B | +18.3% | +18.5% | 164.8 | 4.6% |
|
OHI
Omega Healthcare Investors Inc
|
$13.90B | +4.9% | +13.2% | 16.3 | 4.2% |
|
AHR
American Healthcare REIT, Inc.
|
$11.83B | +15.4% | +9.1% | 78.6 | 10.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOC | -2.9% | -7.6% | +20.2% | -4.8% | +29.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.3% | -12.1% | +6.4% | -8.7% | +15.4% |
Capital returns
Latest dividend
$0.102
/ share · ex Jul 20, 2026
Declared · upcoming
$0.1017
/ share · ex Aug 17, 2026
Paid (TTM)
$1.224
/ share · 12 payouts
Dividend yield (TTM, derived)
5.89%
Buyback program
· as of Jul 30, 2026
Authorized
$500.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
765880
CUSIP
42250P103
13F (30d)
697 filings
665 filers
Visit website
Investor relations